



Press release

Complix selects first Alfabody™ development candidate

Hasselt, October 25, 2011 – Complix NV, a biopharmaceutical company focused on the discovery and development of Alfabodies™, a novel class of protein therapeutics, announced today that it has progressed its first Alfabody™ product, CMPX-1023, into preclinical development. CMPX-1023 is under development for treatment of autoimmune diseases and inflammation. Complix has achieved this important milestone less than 12 months after starting the discovery program for this compound, illustrating the efficiency of its proprietary Alfabody™ discovery engine. CMPX-1023 is Complix's first Alfabody™ entering the development phase. Complix has other ongoing discovery programs for Alfabody™ therapeutics against autoimmune and viral diseases.

CMPX-1023 is a novel therapeutic Alfabody™ that binds with high affinity and selectivity to a key functional epitope of an undisclosed autoimmune disease target. In preclinical models CMPX-1023 has demonstrated impressive potency and selectivity. Given these promising results, CMPX-1023 has the potential to become a valuable therapeutic for treatment of autoimmune disorders, with a superior safety profile as compared to currently marketed drugs. CMPX-1023 was selected from a panel of more than 20 potent antagonists obtained in this program against the defined target.

Complix anticipates to file an Investigational New Drug (IND) application for CMPX-1023 in the first half of 2013.

Dr. Mark Vaeck, CEO of Complix, commented: "We are extremely pleased with the speed at which our first therapeutic Alfabody™ product candidate reached the development stage. It is a clear endorsement of the power of our discovery engine that enables to rapidly generate multiple promising leads against important disease targets."

The Alfabody™ discovery platform applies rational design to generate optimized lead compounds with unrivalled binding affinity to preselected epitopes of functionally important disease targets. Often such crucial target epitopes are difficult or impossible to address with conventional antibody technology or other drug screening platforms.

About Complix:

Complix is a biopharmaceutical company engaged in the discovery and development of Alfabodies™, a novel and proprietary class of biopharmaceuticals with exceptional properties that offer significant advantages over existing protein based therapies. Alfabodies™ display a stability approaching that of small chemicals and the specificity of antibodies. They can bind with high affinity and selectivity to a wide range of disease targets, including targets or target epitopes that are difficult or impossible to address with



antibodies or other therapeutic protein classes. Due to their unique stability and versatility Alphabodies™ have the potential to be formulated for non-injectable routes of administration. Complix's R&D focus is on the development of novel Alphabody™ based therapies for autoimmune diseases such as rheumatoid arthritis, psoriasis and inflammatory bowel disease, and for viral diseases such as influenza, HIV and RSV.

Through the filing of several broad patent applications Complix has established a strong intellectual property position on its Alphabody™ platform and various applications. Because the Alphabody™ structure is totally unrelated to immunoglobulins, Alphabodies™ are independent of antibody based patent claims and offer a unique freedom-to-operate position. In 2010 Complix raised EUR 7 million through a Series A equity financing round, with Vesalius Biocapital, LRM and Crédit Agricole Private Equity as main investors. The Company is headquartered in Hasselt (Belgium) in the Life Sciences incubator BioVille, and has research facilities in Ghent (Belgium) and in Luxembourg. Complix has established a fully owned subsidiary in Luxembourg and has a strategic alliance with the public research institute CRP-Santé.

www.complix.com

Contacts

Complix NV

Dr. Mark Vaeck, CEO, +32 9 261 69 40

mark.vaeck@complix.com